Navigation Links
K-V Pharmaceutical Secures Commitment for $85 Million Loan, Reaches Agreement with Senior Noteholders on Principal Terms of Plan of Reorganization
Date:12/12/2012

ST. LOUIS, Dec. 12, 2012 /PRNewswire/ -- K-V Pharmaceutical Company ("K-V" or "the Company") today announced that it has received a commitment from lenders led by an affiliate of Silver Point Finance LLC for $85 million in senior secured post-petition debtor-in-possession ("DIP") financing, which the Company intends to use to, among other things, satisfy the terms of its recently filed settlement agreement with Hologic, Inc. ("Hologic Settlement"), provide additional financial flexibility during the pendency of the Company's Chapter 11 proceeding and fund certain payments under a proposed reorganization plan.  The new DIP financing, the Hologic Settlement and the reorganization plan (and related disclosure statement)  are each subject to approval of the U. S. Bankruptcy Court for the Southern District of New York, the Honorable Judge Allan L. Gropper presiding.

The Hologic Settlement confirms K-V's continued ownership of Makena® and will resolve all bankruptcy related disputes between K-V and Hologic, and provides for mutual releases of all claims between the parties. 

Under the proposed reorganization plan, K-V expects to emerge from Chapter 11 with its entire product portfolio, including Makena®, Clindesse®, Gynazole-1® and Evamist®.  The Company has provided and is committed to continue to provide its women's health care products without interruption to meet the needs of the health care providers and patients it serves.

Prior to the funding of the DIP financing facility, K-V intends to file with the Bankruptcy Court a proposed reorganization plan, a related disclosure statement, and a plan support agreement (PSA) with an ad hoc group of senior secured noteholders.  The principal terms of the proposed reorganization plan are contained in a plan term sheet filed with the motion to approve the DIP financing filed with the Bankruptcy Court, which together with other documents from the Chapter
'/>"/>

SOURCE K-V Pharmaceutical Company
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. Internal and External Communications Excellence for the Pharmaceutical Industry: Increasing Organizational Effectiveness
3. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
4. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
5. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
6. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
7. The respective roles of the public and private sectors in pharmaceutical innovation
8. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
9. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
10. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
11. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2014)... , Sept. 1, 2014 Reportlinker.com announces ... in its catalogue: India Solid Waste ... http://www.reportlinker.com/p02350445/India-Solid-Waste-Management-Vehicles-Market-Forecast-and-Opportunities-2019.html In ... the main governing bodies responsible for complete handling ... On an average, around 135,000 MT solid waste ...
(Date:9/1/2014)... The global oligonucleotide synthesis market is expected ... million in 2014, growing at a CAGR of ... synthesis market is categorized on the basis of ... The synthesized oligonucleotides segment is expected to register ... market during the forecast period, owing to an ...
(Date:9/1/2014)... (PRWEB) September 01, 2014 The ... and Diagnostics report provides comprehensive understanding and unprecedented ... entered into by the worlds leading life science ... and analysis of how and why companies enter ... a prospective partner’s negotiated deals terms provides critical ...
(Date:8/31/2014)... 31, 2014 Wockhardt Limited today announces a ... Anti-Infective research when two of its drugs, WCK 771 ... Product (QIDP) status from U.S. Food & Drug Administration ... against pathogens which have a high degree of unmet ... for Disease Control (a top U.S. government health and ...
Breaking Biology Technology:India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 2India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 3India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 4India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 5India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 6India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 7India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 89.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 29.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 39.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 49.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 5Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 2Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 3Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 4U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 2U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 3
... 2008 Diffusion,Pharmaceuticals LLC, a clinical-stage drug-development ... action that enhances,oxygen diffusion, today announced that ... entitled "Bipolar Trans Carotenoid Salts and Their ... of first-in-class new chemical entities,known as trans ...
... Mass., April 8, 2008 Caliper Life,Sciences, Inc. (Nasdaq: ... Meeting,of Stockholders will be held on June 3, 2008, ... 68 Elm Street, Hopkinton, Massachusetts. The record,date for Caliper ... 16,2008., About Caliper Life Sciences, Caliper Life ...
... pain reliever lands its first national retail drug ... ... ALCiS Health, Inc., a,provider of patented pain relief products, today announced ... cream, ALCiS Daily Relief, at all of its 6,237 stores.,Its introduction onto ...
Cached Biology Technology:Diffusion Pharmaceuticals Announces Issuance of U.S. Patent No. 7351844, Titled 'Bipolar Trans Carotenoid Salts and Their Uses,' for Its Family of First-In-Class Molecules 2ALCiS(R) Daily Relief Now Available at Walgreens 2
(Date:9/1/2014)... An increasing amount of research shows an association between ... sedentary lifestyle. Now, a new Cornell University study points ... programs might lead people to eat twice as much ... an action movie while snacking your mouth will see ... on the new article just published in the ...
(Date:9/1/2014)... has improved steadily in recent yearsspurred in large part ... poor and disparities continue to widen among socioeconomic and ... School of Public Health (HSPH). , "The study provides ... efforts by many groups and individuals to improve U.S. ... indicates that these efforts need to be expanded," said ...
(Date:9/1/2014)... The quality of the U.S. diet showed some modest ... of a reduction in the consumption of unhealthy trans ... between the rich and the poor. , , An ... and some cancers. Eating a healthy diet is an ... outcomes. Evaluating population trends in diet quality is important ...
Breaking Biology News(10 mins):Can action movies make you fat? 2Quality of US diet shows modest improvement, but overall remains poor 2Quality of US diet shows modest improvement, but overall remains poor 3Quality of US diet improves, gap widens for quality between rich and poor 2Quality of US diet improves, gap widens for quality between rich and poor 3
... a Global Information System will provide valuable information for ... Institute of Environmental Health Sciences (NIEHS), one of the ... the most up-to-date data to public health and safety ... maps, as well as demographic information for local populations. ...
... Some 12.3 percent of all babies -- 499,008 infants -- ... according to the report released by the National Center for ... 480,000 babies) in 2002 -- and an increase of more ... in 1981. The prematurity rate was 9.4 in 1981; it ...
... the world's vaccine manufacturers will be in a race ... a new technique to more efficiently produce the disarmed ... vaccine in large quantities, life-saving inoculations may be available ... as governments worldwide prepare for a predicted pandemic of ...
Cached Biology News:NIEHS launches website with information for assessing environmental hazards from Hurricane Katrina 2UW scientists report a new method to speed bird flu vaccine production 2UW scientists report a new method to speed bird flu vaccine production 3
One-step, microplate or cuvet, colorimetric, linear detection range 0.7 mg/dL to 35 mg/dL. Procedure: 5 min....
assays for phosphatase, lipase, nucleoside triphosphatases (ATPase, GTPase etc). HTS and follow up studies for phosphatase inhibitors. Quantitation of phosphate content in protein, lipids, and DNA....
One-step, microplate or cuvet, colorimetric, detection range 0.1 mg/dL to 3 mg/dL. Procedure: 10 min....
Human DCIR/CLEC4A Phycoerythrin MAb (Clone 216110)...
Biology Products: